AbbVie to Acquire Allergan, Botox’s Maker, for $63 Billion
The deal would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira.
View original article
Author:
The deal would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira.
View original article
Author: